Connect with us

Government

4 Medical Diagnostic Stocks To Watch Next Week

With the rising concern of COVID-19, should you check out these medical diagnostic stocks?
The post 4 Medical Diagnostic Stocks To Watch Next Week appeared first on Stock Market News, Quotes, Charts and Financial Information | StockMarket.com.

Published

on

Are These The Best Medical Diagnostic Stocks To Buy Right Now?

Medical diagnostic stocks are a branch of health care stocks in the stock market. As the name suggests, these are companies that specialize in diagnostic testing and equipment. The importance of a good diagnosis should not be understated. Accurate and efficient diagnostic procedures are essential for doctors to create a proper treatment plan that would fully benefit the patient. A fatal disease can be detected early with proper diagnostic testing and this could potentially save millions of lives.  

We can see companies such as Abbott Laboratories (NYSE: ABT) and Quidel Corporation (NASDAQ: QDEL) playing an important role in combating the global pandemic. For instance, Quidel which specializes in rapid diagnostic testing solutions would run COVID-19 testing programs to support the reopening of schools. It would even be responsible for staffing test locations, coordinating sample collection, running the tests, and ultimately reporting results to the Public Health departments. Given the importance of this industry right now, some would argue that it is a good time to add medical diagnostic stocks to your portfolio. If you share the same sentiment, here are 4 names to watch in the stock market today

Top Medical Diagnostic Stocks To Watch 

Laboratory Corp. of America Holdings

Firstly, we have the healthcare diagnostic company, Laboratory Corp. Put simply, it is a life sciences company that guides patient care, providing clinical laboratory and end-to-end drug development services. The company offers a variety of frequently requested testing through a network of primary and specialty laboratories across the United States. LH stock has been on a bullish run this year, showing gains of over 37%. 

Earlier this month, Laboratory Corp announced the availability of therascreen KRAS PCR Mutation Analysis. This is a companion diagnostic to identify patients with non-small cell lung cancer who are eligible for treatment with LUMAKRAS (sotorasib), a new treatment option developed by Amgen (NASDAQ: AMGN). With this, physicians will have immediate access to ensure every patient who may benefit from sotarasib is appropriately identified and treated. 

Besides that, the company is also helping to sequence thousands of complete coronavirus genomes each week from positive patient samples. It is utilizing Molecular Loop Biosciences, Inc’s SARS-CoV-2 Research Sequencing Panel to carry out the sequencing. This initiative is part of a U.S. Centers for Disease Control and Prevention (CDC) effort to track the spread of SARS-CoV-2 variants throughout the country. With so many recent developments, could we expect strong second-quarter financial results next week? If you think so, then LH stock could be worth adding to your watchlist right now.

LH stock
Source: TD Ameritrade TOS

Read More

Co-Diagnostics Inc 

Following that, we have the molecular diagnostics company Co-Diagnostics. For starters, it is a company that specializes in diagnostic technology. Its reagents are used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. Not to mention, it also sells diagnostics equipment from other manufacturers as self-contained lab systems (MDx device). 

CODX stock soared by over 21% on Thursday. Let us see what could be the catalyst for this movement. Yesterday, the company announced that it has added to its suite of intellectual property protection. It was awarded a patent from the Republic of Korea’s Intellectual Property Office for the Company’s CoPrimer technology. Co-Diagnostics also stated that most of its tests sold have been to repeat customers which indicates that its customers have come to depend on the quality of its CoPrimer assays. All these further validate the uniqueness and versatility of the CoPrimer platform. 

It is noteworthy that among the various diagnostic products using CoPrimer technology to have received regulatory clearance is the Logix Smart COVID-19 Test kit. In fact, the company has sold millions of the kits since the onset of the pandemic. It appears that it is effective in detecting all known strains which include the Delta variant of SARS-CoV-2. Now, it does seem like an exciting time for the company with its recent validation. So, would you bet on CODX stock to be the next big diagnostic stock?  

medical diagnostic stocks (CODX stock)
Source: TD Ameritrade TOS

[Read More] Good Stocks To Invest In Today? 4 5G Stocks To Watch

Thermo Fisher Scientific Inc 

Another top medical diagnostic company in the stock market today would be Thermo Fisher. It offers its products and services through various brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services. TMO stock has been trading sideways for most of the year. That said, we are starting to see a bullish price action over the past month.  

Recently, Thermo Fisher announced an expansion of its collaboration with My Green Lab. Thermo has set a goal to obtain Accountability, Consistency, and Transparency (ACT) labeling for its entire cold temperature storage portfolio by the end of 2021. The company expects to ACT label more than 1,200 additional SKUs. This would enable research, pharmaceutical, and clinical laboratories to achieve their sustainability objectives. Certainly, this is a commendable commitment by the company as environmental issues have been gaining traction lately. 

Furthermore, it has opened a new cGMP plasmid DNA manufacturing facility in Carlsbad. This would enable it to meet the rapidly growing demand for plasmid DNA-based therapies and vital mRNA-based vaccines. Also, it addresses the issue of demand outpacing supply for commercial plasmid DNA globally. All things considered, would you be watching TMO stock? 

top medical diagnostic stocks (TMO stock)
Source: TD Ameritrade TOS

[Read More] 4 Robotics Stocks To Watch Amid Rising Shifts To Automation

Quest Diagnostics Inc 

To sum up the list, we have Quest Diagnostics. Essentially, it is a provider of diagnostic information services. Its Diagnostic Information Services business develops and delivers diagnostic testing information and services. Meanwhile, its Diagnostic Solutions group includes its risk assessment services business, which offers solutions for insurers, and its healthcare information technology businesses. 

On Thursday, Quest announced its second-quarter earnings report. The company showed a faster than expected recovery of its core business. It reported revenue of $2.55 billion, up 39.5% year-over-year. Also, its diluted earnings per share came in at $4.96, representing an increase of a whopping 264.2%. This strong financial outlook puts the company in a strong position to continue its momentum for the remainder of 2021. 

The company also went into collaboration with CLX Health to provide access to COVID-19 molecular diagnostic testing. This aims at people who are seeking to attend live events nationwide or travel from the U.S. to destinations around the world. Given these positive developments for the company, would DGX stock be a top diagnostic stock to watch now?

DGX Stock
Source: TD Ameritrade TOS

The post 4 Medical Diagnostic Stocks To Watch Next Week appeared first on Stock Market News, Quotes, Charts and Financial Information | StockMarket.com.

Read More

Continue Reading

Spread & Containment

Addressing the HIV epidemic in Eastern Europe and Central Asia

Working in partnership will be key, says Alex Kalomparis, vice president, public affairs, international at Gilead Sciences. 2021
The post Addressing the HIV epidemic in Eastern Europe and Central Asia appeared first on .

Published

on

Working in partnership will be key, says Alex Kalomparis, vice president, public affairs, international at Gilead Sciences.

2021 marks 40 years since the first cases of HIV were reported. In that time, over 79 million people have been diagnosed with HIV, with more than 36 million dying from AIDS-related illnesses, more than any other infectious disease.

While there has been incredible progress in the HIV response, nearly 38 million people are living with HIV, with more than a million new cases every year, jeopardising the goal to end AIDS as a public health threat by 2030.

HIV places enormous burdens on the communities it affects most, straining health systems and government budgets. In the era of the global COVID-19 pandemic, where health systems are already stretched to breaking, it is tempting to cut costs in other areas, including HIV. If commitment to the HIV response wanes, the progress we have made is at risk, leading to increases in new infections in regions that can least afford to tackle them.

“An epidemic somewhere is an epidemic everywhere”

Throughout the COVID-19 pandemic, we have seen the temptation to focus on one’s own backyard, isolate oneself from the rest of the world, and believe one is safe and protected. We know now that this protection is an illusion. Regardless of the protections we erect in our own countries, allowing public health crises to persist in other parts of the world threatens our own progress and safety.

The message is clear: an epidemic somewhere is an epidemic everywhere. To find our way out of a pandemic, we must broaden our ideas of how to respond, and address the problems and inequities that allow diseases to thrive in other parts of the world. To be effective, our response must be global.

The same is true for HIV. HIV has persisted for 40 years, and is still here because root problems continue to drive the epidemic: stigma and discrimination, poverty, lack of access to services and treatments, lack of access to education, and the marginalisation of the people and communities most at risk of HIV. These are not issues that can be addressed by any one government, group, or company. They can be addressed only in partnership with one another, and by engaging those key marginalised communities in our effort to end the HIV epidemic.

Whilst the global community has the tools it needs to meaningfully address new HIV infections, HIV is on the rise in Eastern Europe and Central Asia (EECA). Unlike other regions in the world, rates of HIV in EECA have increased, with infections up by 72 per cent, and AIDS-related deaths up by 24 per cent since 2010.

Working with the Elton John AIDS Foundation

However, across EECA, a range of community partners are making significant contributions in the fight against HIV, such as the first wave of the RADIAN ‘Unmet Need’ fund and Model City grantees, previously announced in 2020. In the first nine months of the programme, these partners have already reached more than 12,000 people from vulnerable communities directly with services, initiating life-saving care in over 2,000 people living with HIV.

RADIAN, a ground-breaking partnership between Gilead Sciences and the Elton John AIDS Foundation, works with local experts to target new HIV infections and deaths from AIDS-related illnesses in EECA in the communities most vulnerable to HIV.

Focusing on the groups most affected by HIV in EECA (eg men who have sex with men, transgender people, sex workers, and people who use drugs), RADIAN engages with groups led by these communities and are sensitive to the difficulties unique to the region.

“We all have one common goal: ending HIV”

Anne Aslett, CEO of the Elton John AIDS Foundation, is clear that for the partnership to reach its goals, it’s crucial to listen to and amplify the voices of people for whom HIV is a tangible, daily reality.

“They understand better than anyone the challenges associated with the virus, and what works to stop it. No matter where we are in the world, we must partner with them, and follow their leadership. We are proud of our RADIAN partnership with Gilead, to champion the vital work of communities to bring an end to the AIDS epidemic in Eastern Europe and Central Asia.”

Companies like Gilead Sciences provide industry leading expertise, while Governments bring an understanding of health systems and funding, developing an infrastructure that enables access.

However, these efforts need community leadership because they know best how to ensure people can access those systems to get tested, and adhere to medication. They understand the fears and sensitivities, the strengths and stigma within those communities, the nuances that make the difference in linking their members to the care they need. No two regions of the world experience the ‘same’ HIV epidemic. People living with HIV are critical to the success of any HIV response.

This autumn, RADIAN will launch a campaign telling the inspirational stories of ordinary, yet remarkable, community members who are taking action to turn the tide of the HIV epidemic in EECA.

We all have one common goal: ending HIV. It is crucial that we all understand the role we can play to achieve this. Our access to global networks of public health expertise, government funding, and innovative HIV treatments are meaningless unless they are used in service of people living with, and at risk of, HIV. They are the core of any successful response, regardless of country or region. Working in partnership with them is the key to ending HIV. By respecting them as leaders and giving them the seat at the head of the table, we make our work more effective and responsive to local needs, bringing us closer to the end of the HIV epidemic globally.

About the author 

Alex Kalomparis is vice president, public affairs, international at Gilead Sciences. He joined the company in January 2017 and is responsible for all communications and patient advocacy activities across Africa, Asia, Australia, Canada, Europe, Latin America and the Middle East. Prior to that Alex held senior communication roles with a number of consumer and pharmaceutical companies, including Unilever, Rolls Royce, Novartis, Roche, AstraZeneca and GlaxoSmithKline.

The post Addressing the HIV epidemic in Eastern Europe and Central Asia appeared first on .

Read More

Continue Reading

Science

Your immune system is as unique as your fingerprint – new study

New discovery could help scientists develop more targeted drugs and vaccines.

Published

on

Christoph Burgstedt/Shutterstock

Every person appears to have a unique immune system. My colleagues and I discovered this immune diversity after charting antibodies in the blood from healthy and sick people. The discovery could help explain why, for example, COVID vaccines appear to be less effective for some people. At the same time, it points to the possibility of identifying and retrieving particularly effective antibodies from individuals and using them to cure others.

In our daily life, our body is confronted and attacked by many germs that use clever tricks to enter our body, aiming to take control. Luckily, we have a powerful defence: our immune system.

With a well-functioning immune system, we can combat most of the germs that continuously and aggressively approach us. Part of our arsenal of weapons to neutralise invading germs are protein molecules called antibodies. These antibodies are abundant in the blood, streaming throughout our body, forming the first line of defence when a new nasty germ appears.

Each different germ requires a different arsenal of weapons (antibodies) to combat them most efficiently. Luckily, our body has provided us with a means to make millions to even billions of different antibodies, but they cannot all be made at the same time. Often, specific antibodies are only made as a response to a particular germ.

If we are infected by bacteria, we start to make antibodies to attack and kill those bacteria. If we are infected by the coronavirus, we start to make antibodies to neutralise that virus. When infected with the flu virus, we again make other ones.

How antibodies fight coronavirus.

How many different antibodies are made at a given moment and are thus present in our blood, was not known. Many scientists estimated it to be over several billion and hence almost immeasurable. Using a few droplets of blood and a technique called mass spectrometry, my colleagues and I were able to capture and measure the number of different antibodies in the blood and also assess the exact concentration of each of them.

Two surprises

Although theoretically, our body has the capacity to make trillions of different antibodies, a first surprise came when we noted that in the bloodstream of both healthy and diseased people just a few tens to hundreds of distinct antibodies were present at high concentrations.

Monitoring these profiles from just a few droplets of blood, we were surprised for a second time when we noticed that the way the immune system responds to germs varies highly from person to person, with each person’s antibody profile being unique. And the concentrations of these antibodies change in a unique way during illness or after a vaccination. The results may explain why some people are more prone to becoming ill from flu or COVID, or why they recover faster from some illnesses than others do.

Until now, scientists considered it impossible to accurately map the highly complex mixture of antibodies in the blood. But mass spectrometry separates substances based on their molecular composition, and since each specific antibody has a distinct molecular composition, we were able to use a refinement of the technique to measure all antibodies individually.

The method has been used to measure antibody profiles in about 100 people, including COVID patients and people vaccinated with different COVID vaccines. Not once did we encounter the same antibodies in two different people, even if they had received the same vaccine. It’s safe to say that everyone’s antibody profile is as unique as their fingerprint.

Even though the differences in antibodies are small, they greatly influence the course of a disease. If someone makes fewer antibodies against a certain germ, or only antibodies that are less effective at killing the germ, then a disease might strike harder or several times. On the other hand, if people produce antibodies that are excellent at neutralising the germ, that antibody could be produced therapeutically and used to vaccinate or treat patients.

Our research creates opportunities to make optimal vaccinations and drugs tailored to an individual’s immune system. By mapping someone’s antibody profile, you can track how their body responds to a vaccine or infection – or even a drug treatment. This way, you can also check whether the body produces enough of the desired antibodies, for example, those against the coronavirus. If they don’t produce enough, you can consider offering booster shots or antibodies that worked for other people.

Albert Heck receives funding from the Netherlands Organization fro Scientific Research

Read More

Continue Reading

Government

The Bloc’s Secrets of Success: 5 Ways The Health Creative Agency Won 200 Awards

As a global pandemic has reshaped society, The Bloc has been at the forefront of changing not just what stories get told about healthcare, but how they are told. In doing so, the health creative agency has won more than 200 film and advertising awards…

Published

on

The Bloc’s Secrets of Success: 5 Ways The Health Creative Agency Won 200 Awards

The Bloc achieved unprecedented levels of acclaim and recognition by embracing creativity, racial justice, technology, new practices, and people

New York, NY, September 22 – Over the past two years, The Bloc has redefined health creative to become one of America’s most talked about agencies. As a global pandemic has reshaped society, The Bloc has been at the forefront of changing not just what stories get told about healthcare, but how they’re told. In doing so, they’ve won over 200 film and advertising awards in 2020 and 2021. Recently, The Bloc became the first ever health agency listed on the “Of The Year” ranking for the entire Cannes Lions International Festival of Creativity. In addition, The Bloc is a founding member of The BlocPartners, the acclaimed global network of independent health creative agencies. The BlocPartners recently placed second in the “Health Network of the Festival” category at the Cannes Lions Health Festival.

The Bloc CEO Jennifer Matthews (PRNewsfoto/The Bloc)

“The work we’ve been so awarded for lately has been a natural extension of our motto ‘Be Great to Do Good,’” said Jennifer Matthews, CEO at The Bloc. “Health is life. It deserves the very best in creative excellence.”

  1. Invest in Hollywood Level Filmmaking 

A man walks through a futuristic train station, suffering from a cough, and decides to seek help from an automated doctor. That’s the premise of The Bloc’s award-winning short film Instant Doctor. Made so as to give thanks to doctors and released on National Doctor’s Day (March 30, 2020), the film highlighted the importance of the human element in healthcare by showing a world where medicine is done via machines.  

Instant Doctor won the Grand Jury Award for Best Short at the New York International Film Awards and was declared the Best Sci-fi Short Film at the 2020 Rhode Island International Film Festival.

“Instant Doctor has shown the industry that healthcare advertising can have not just the production quality but also the storytelling excellence of Hollywood movies,” said Bernardo Romero, Chief Creative Officer at The Bloc. “Healthcare has never been more important, which means health creative should be of the same quality as what you would see in a movie theatre or stream on Netflix.”

  1. Tackle the Biggest Issues – Including Racism and Racial Bias in Healthcare

Some of The Bloc’s most acclaimed recent work has centered around racial justice, both in healthcare and in the broader world. 

In early 2020, The Bloc, in partnership with acclaimed ballet dancer Ingrid Silva’s EmpowHer New York, released “The Call,” a short film where an actress went undercover on nursing advice hotlines to expose racial disparities in healthcare treatment. 

The Bloc went on to work with Ingrid on two more films. First came Skindeep, an animated story about racial trauma told through watercolor frames by Black women illustrators. Skindeep was followed by Making Space, a documentary about Ingrid’s life journey which premiered at Cannes Lions. 

In partnership with the National Black Child Development Institute, The Bloc created ABC’s of Survival, a tear-apart book for black children and their parents. The book aims to support mental health and change laws by including postcards that can be sent to congress. The ebook can be found at abcsofsurvival.com.

  1. Hire and Promote the Best People

The Bloc continues to grow rapidly and has recently hired Stuart Goldstein as COO and promoted Antoinette Bobbitt to EVP, strategy director. Stuart will be The Bloc’s first COO, and he’ll oversee the management for over 4,500 projects a year, with the goal of increasing efficiency and profitability. Meanwhile, Antoinette will ensure that The Bloc’s competitive differentiation is present in all client work.

The Bloc’s commitment to its employees was underscored this summer when Fortune magazine listed it as one of the best workplaces in New York for 2021. The Bloc is one of three advertising agencies on the list, and the only health creative agency focused exclusively on health.

  1. Get High Tech

More and more agencies are realizing that their creative skills can be used to power tech innovations, and The Bloc has focused on the development of tech to address pressing health needs. At the beginning of the pandemic, The Bloc pioneered SafeCode, a device concept which combined a bar-code scanner with UV light to help stop the spread of disease on delivery packages. 

The Bloc has also created a tool to aid mental health. At the end of 2020, they worked with Rockwell Ventures to create Scrollaby, an app which takes the habit of “doomscrolling” and turns it into a sleep aid, with over 1,000 pieces of custom content that support rest and relaxation.

  1. Rethink Agency Practices

To expand upon the capabilities it has developed, The Bloc has established new practice areas that distinguish it in the healthcare agency space.

One new practice area is The Bloc Science Foundry, which applies behavioral science and scientific expertise to medical communications. The other is The Bloc Storytellers

And this year, The Bloc announced its Storytellers department, which is dedicated to bringing unsurpassed production and narrative quality to healthcare creative. Storytellers seeks to replicate the success The Bloc has had with The Call, Skindeep, and Instant Doctor. The Bloc is currently searching for the best creative minds from the film, theater, and TV industries to join their team. Resumes can be sent to storytellers@thebloc.com.

 

About The Bloc

The Bloc is a leading independent health creative agency in the United States. Celebrating 21 years in 2021, The Bloc delivers comprehensive omnichannel communications for audiences across the health spectrum and partners with innovative clients who are doing some of the most meaningful and exciting work in health today. A founding member of The BlocPartners, the leading global network of independent health creative agencies, The Bloc’s work has been globally recognized for creativity and innovation. For more information, visit www.thebloc.com.

 

Read More

Continue Reading

Trending